27 recruiting. 27 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Recruiting 27 |
| Phase 1 | 5 | Recruiting 5 |
| Phase 3 | 2 | Recruiting 2 |
Follow Cardiovascular Abnormalities: new trials by email Literature Review of Cardiovascular Abnormalities trials Research Report on Cardiovascular Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATR 1072 in Participants With PRKAG2 Syndrome ATR 1072 - Cardiac Glycogenosis, Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Atrium Therapeutics | 37 | 2026-09-14 | 2026-09-18 |
| Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST) Bleomycin Sulfate - Vascular Malformations | Phase 2 | Recruiting | Institute of Oncology Ljubljana | 140 | 2026-09-10 | 2026-10-09 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-10-29 |
| DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Recruiting | Diagonal Therapeutics, Inc. | 93 | 2026-06-04 | 2026-09-08 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) baseline lead-in, THRV-1268 - Long QT Syndrome (LQTS) 2 | Phase 2 / Phase 3 | Recruiting | Thryv Therapeutics, Inc. | 84 | 2026-03-07 | 2026-09-21 |
| Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations Bevacizumab, Placebo - Cerebral AV Malformation | Phase 2 / Phase 3 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 54 | 2026-01-16 | 2026-01-22 |
| Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children End-expiratory lung volume optimization maneuver with PEEP titration, Standard Care (in control arm) - Congenital Heart Disease, Cardiopulmonary Bypass | Phase 1 / Phase 2 | Recruiting | Charite University, Berlin, Germany | 80 | 2025-12-05 | 2026-10-15 |
| 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs alpelisib (BYL719) - Vascular Anomalies, Vascular Anomaly | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 61 | 2025-08-27 | 2026-10-19 |
| 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs Trametinib - Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 45 | 2025-08-27 | 2026-10-19 |
| An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations Everolimus 10mg daily - Vascular Malformations | Phase 2 | Recruiting | Xuanwu Hospital, Beijing | 10 | 2025-07-01 | 2025-09-05 |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) RLY-2608, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations | Phase 2 | Recruiting | Relay Therapeutics, Inc. | 277 | 2025-06-13 | 2026-08-25 |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System Cardiohelp device (VA-ECMO), Heparin, Bivalirudin - Heart Failure, Cardiogenic Shock | Phase 2 | Recruiting | Stanford University | 50 | 2025-04-15 | 2026-08-10 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy Tideglusib, Placebo - Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy | Phase 2 | Recruiting | Hamilton Health Sciences Corporation | 120 | 2025-03-21 | 2026-03-12 |
| A Study of Enalapril in Treatment of Venous Malformations Enalapril - Venous Malformation, Pain | Phase 2 | Recruiting | Oslo University Hospital | 12 | 2025-02-01 | 2025-04-02 |
| Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD Spironolactone, Placebo - Arrhythmogenic Right Ventricular Dysplasia | Phase 2 | Recruiting | Hospices Civils de Lyon | 120 | 2024-12-20 | 2026-02-09 |
| Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Sertraline, Placebo - Neurodevelopmental Disorders, Autism | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 130 | 2024-09-16 | 2026-07-27 |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies Trametinib tablet, Standard therapy - Cardiomegaly, Noonan Syndrome | Phase 2 | Recruiting | Medical University of Warsaw | 40 | 2024-08-01 | 2024-08-15 |
| Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT Standard Dose - Ibuprofen oral suspension, Precision Dose - Ibuprofen oral suspension - Patent Ductus Arteriosus, Preterm | Phase 2 | Recruiting | Hamilton Health Sciences Corporation | 26 | 2024-07-04 | 2025-08-27 |
Showing 20 of 27. Sign in to see all of them.
Vascular Malformations (8) · Arteriovenous Malformations (4) · Cardiomyopathies (3) · Heart Defects, Congenital (3) · Telangiectasia, Hereditary Hemorrhagic (3) · Arrhythmogenic Right Ventricular Dysplasia (2) · Cardiovascular Diseases (2) · DiGeorge Syndrome (2) · Ductus Arteriosus, Patent (2) · Heart Failure (2) · Intracranial Arteriovenous Malformations (2) · Lymphatic Abnormalities (2) · Neoplasms (2) · 22q11 Deletion Syndrome (1)
Congenital Abnormalities (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (27) · Cardiovascular Diseases (25) · Heart Diseases (11) · Heart Defects, Congenital (9) · Pathological Conditions, Signs and Symptoms (9) · Vascular Diseases (9) · Hemic and Lymphatic Diseases (7) · Pathologic Processes (6) · Vascular Malformations (6) · Genetic Diseases, Inborn (4) · Lymphatic Diseases (4) · Nervous System Diseases (4) · Nervous System Malformations (4)
Alpelisib (2) · Standard of Care (2) · trametinib (2) · Acetaminophen (1) · Bevacizumab (1) · Bleomycin (1) · Blood Vessel Prosthesis (1) · Capsules (1) · Enalapril (1) · Everolimus (1) · Heparin (1) · Ibuprofen (1) · Selective Serotonin Reuptake Inhibitors (1) · Sertraline (1) · Sirolimus (1)
Children's Hospital of Philadelphia (2) · Hamilton Health Sciences Corporation (2) · Atavistik Bio, Inc (1) · Atrium Therapeutics (1) · Centre Hospitalier Universitaire, Amiens (1) · Charite University, Berlin, Germany (1) · Diagonal Therapeutics, Inc. (1) · Dr. Romain Lazor (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Holland Bloorview Kids Rehabilitation Hospital (1) · Hospices Civils de Lyon (1) · Institute of Oncology Ljubljana (1) · Jona Hattangadi-Gluth (1) · Medical University of Warsaw (1) · Mount Sinai Hospital, Canada (1)
United States (10) · Canada (5) · France (5) · Australia (4) · Belgium (2) · China (2) · Germany (2) · Ireland (2) · Hong Kong (1) · Italy (1) · New Zealand (1) · Norway (1) · Poland (1) · Slovenia (1) · Spain (1)
Amish Jain, MD PhD (1) · Caroline Ozment, MD (1) · Christopher Breuer, MD (1) · Dr. Evdokia Anagnostou (1) · Jason D Roberts, MD MAS (1) · Jona Hattangadi-Gluth, MD (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Lynn Sleeper, ScD (1) · Mark Galantowicz, MD (1) · Paul Szabolcs, MD (1) · Petra Witt Nystrom, MD, PhD (1)
PMID 28652319, PMID 31910860, PMID 37979797, PMID 40041314, PMID 42660999
2023 (2), 2025 (1), 5UH3HL148693 (1), R01CA238783 (1)